Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Mar;41(3):583–586. doi: 10.1128/aac.41.3.583

In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.

H Thadepalli 1, U Reddy 1, S K Chuah 1, F Thadepalli 1, C Malilay 1, R J Polzer 1, N Hanna 1, A Esfandiari 1, P Brown 1, S Gollapudi 1
PMCID: PMC163755  PMID: 9055997

Abstract

The efficacy of trovafloxacin in treating Bacteroides fragilis and Escherichia coli infections was investigated and compared to the efficacy of combined clindamycin and gentamicin therapy in an experimental model of intra-abdominal abscesses in rats. Rats were treated with different doses of CP-116,517-27, a parenteral prodrug of trovafloxacin. Response to treatment was evaluated by mortality rate and elimination of infection (cure rate). Mortality in the control group was 85.4%, whereas in rats treated with trovafloxacin, it was close to 0%. The highest cure rate (89.3%) resulted from the administration of 40 mg of CP-116,517-27 per kg of body weight three times a day (TID) for 10 days (equivalent to 18.15 mg of active drug trovafloxacin per rat per day). The therapeutic response with trovafloxacin was comparable to that of a combination therapy of clindamycin (75 mg/kg) plus gentamicin (20 mg/kg) TID (cure rate, 74%; mortality rate, 5%). The measured peak levels of trovafloxacin in serum and abscess pus were 2.6 +/- 0.3 and 5.2 micrograms/ml, respectively. The tumor necrosis factor alpha levels in the untreated animals were high compared to those for rats treated with trovafloxacin or clindamycin plus gentamicin. These results demonstrate that trovafloxacin as a single agent appears to be as successful as clindamycin plus gentamicin in the treatment of experimental intra-abdominal abscesses in rats.

Full Text

The Full Text of this article is available as a PDF (83.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bach V. T., Thadepalli H. Susceptibility of anaerobic bacteria in vitro to 23 antimicrobial agents. Chemotherapy. 1980;26(5):344–353. doi: 10.1159/000237926. [DOI] [PubMed] [Google Scholar]
  2. Bailly S., Fay M., Roche Y., Gougerot-Pocidalo M. A. Effects of quinolones on tumor necrosis factor production by human monocytes. Int J Immunopharmacol. 1990;12(1):31–36. doi: 10.1016/0192-0561(90)90065-u. [DOI] [PubMed] [Google Scholar]
  3. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986 Apr 17;320(6063):584–588. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  4. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  5. Edelstein P. H., Edelstein M. A., Ren J., Polzer R., Gladue R. P. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 1996 Feb;40(2):314–319. doi: 10.1128/aac.40.2.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Girard A. E., Girard D., Gootz T. D., Faiella J. A., Cimochowski C. R. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother. 1995 Oct;39(10):2210–2216. doi: 10.1128/aac.39.10.2210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gollapudi S. V., Chuah S. K., Harvey T., Thadepalli H. D., Thadepalli H. In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis. Antimicrob Agents Chemother. 1993 Aug;37(8):1711–1712. doi: 10.1128/aac.37.8.1711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jacobs R. F., Tabor D. R. The immunology of sepsis and meningitis--cytokine biology. Scand J Infect Dis Suppl. 1990;73:7–15. [PubMed] [Google Scholar]
  9. Lundblad R., Ekstrøm P., Giercksky K. E. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock. 1995 Mar;3(3):210–215. doi: 10.1097/00024382-199503000-00009. [DOI] [PubMed] [Google Scholar]
  10. Nemunaitis J., Rosenfeld C., Getty L., Boegel F., Meyer W., Jennings L. W., Zeigler Z., Shadduck R. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am J Clin Oncol. 1995 Jun;18(3):189–193. doi: 10.1097/00000421-199506000-00002. [DOI] [PubMed] [Google Scholar]
  11. Neu H. C., Chin N. X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994 Nov;38(11):2615–2622. doi: 10.1128/aac.38.11.2615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Thadepalli H., Bansal M. B., Rao B., See R., Chuah S. K., Marshall R., Dhawan V. K. Ciprofloxacin: in vitro, experimental, and clinical evaluation. Rev Infect Dis. 1988 May-Jun;10(3):505–515. doi: 10.1093/clinids/10.3.505. [DOI] [PubMed] [Google Scholar]
  13. Thadepalli H., Gollapudi S. V., Chuah S. K. Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess. Antimicrob Agents Chemother. 1986 Oct;30(4):574–576. doi: 10.1128/aac.30.4.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Thadepalli H., Gorbach S. L., Broido P., Norsen J. A prospective study of infections in penetrating abdominal trauma. Am J Clin Nutr. 1972 Dec;25(12):1405–1408. doi: 10.1093/ajcn/25.12.1405. [DOI] [PubMed] [Google Scholar]
  15. Thadepalli H., Hajji M., Perumal V. K., Chuah S. K., Gollapudi S. Evaluation of temafloxacin in a rat model of intra-abdominal abscess. J Antimicrob Chemother. 1992 Jun;29(6):687–692. doi: 10.1093/jac/29.6.687. [DOI] [PubMed] [Google Scholar]
  16. Tracey K. J., Lowry S. F., Fahey T. J., 3rd, Albert J. D., Fong Y., Hesse D., Beutler B., Manogue K. R., Calvano S., Wei H. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987 May;164(5):415–422. [PubMed] [Google Scholar]
  17. Weinstein W. M., Onderdonk A. B., Bartlett J. G., Gorbach S. L. Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun. 1974 Dec;10(6):1250–1255. doi: 10.1128/iai.10.6.1250-1255.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yasumoto R., Kawano M., Tsujino T., Iwai Y., Hayashi S., Nishisaka N., Horii A., Kishimoto T. [Seminal plasma cytokines in nonbacterial prostatitis: changes following sparfloxacin treatment]. Hinyokika Kiyo. 1995 Oct;41(10):771–774. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES